Purpose: The purpose of this article is to review the evidence for the hypothesis that the core mechanism of dry eye disease (DED) is inflammation, including evidence from recent basic, clinical, and translational research involving human patients, animal models, and cell cultures. Methods: Using the key words "dry eye + inflammation," the authors conducted a comprehensive search of the PubMed and Web of Science databases for scientific articles published in English between January 1, 1900 and August 30, 2013 on the role of inflammation in DED in cell cultures, animal models, and humans. The resulting articles were then categorized and reviewed. Results: The literature search revealed a total of 458 publications, almost all published after 1992. The percentages of original studies and review articles are 77.29% (354) and 22.71% (104), respectively. Among the original studies, the number of reports on human DED is 200 (43.7%), on animal models is 115 (25.1%), and cell cultures is 39 (8.5%). A yearly distributing plot revealed that 76% were published from 2003 to 2011, 53% from 2008 to 2012, and 11% during the first 9 months of 2013. This distribution signifies a rapidly growing awareness of the importance of inflammation in DED pathogenesis. Conclusions: Inflammation plays a key role in the pathogenesis of DED as evidenced by research using tissue culture, animal models, and subjects with DED. Developing biomarkers for inflammation of the ocular surface will provide improved understanding of the mechanisms leading to DED, classification of the severity of DED, and objective metrics for outcome measures of treatment. The chronicity of the disease suggests that dysregulation of immune mechanisms leads to a cycle of continued inflammation, accompanied by alterations in both innate and adaptive immune responses. Given the underlying mechanism for DED, developing effective and safe antiinflammatory treatments is likely to be beneficial for patients with DED.
D ry eye disease (DED) is a multifactorial disorder of the tear film and ocular surface. 1 Tear film instability and ocular surface inflammation give rise to symptoms of discomfort, visual disturbance, eye dryness, irritation, foreign body sensation, light sensitivity, and itching, all of which eventually reduce a person's quality of life. Effective treatment modalities that can reverse, or at least stop this progression, are scarce.
During the past 20 years, researchers have shown increasing interest in the hypothesis that the core mechanism of DED is inflammation. Using the key words "dry eye + inflammation," the authors conducted a comprehensive search of the PubMed and the Web of Science databases for scientific articles published in English between January 1, 1900 and August 30, 2013 on the role of inflammation in DED in cell cultures, animal models, and humans. The search revealed a total of 458 articles, include 354 original studies (77.29%) and 104 reviews (22.71%). Of the original studies, the percentage involving human subjects was 43.7% (200), animal or animal models was 25.1% (115), and cell or tissue cultures was 8.5% (39) ( Table 1 ). Lists of the 10 most published authors and affiliations on the topic are presented in Tables 2 and 3 . A yearly distributing plot (Fig. 1) shows that, of the total, 76% were published from 2003 through 2012, 53% from 2008 through 2012, and 11% in the first 9 months of 2013.
These reports strongly indicate that DED is an autoimmune disease of the ocular surface and that inflammation plays a key role in determining its progression and resolution. [1] [2] [3] [4] Based on this, DED has the same core mechanism as diverse other diseases, for example, atherosclerosis and rheumatoid arthritis (RA). All these diseases display the same basic characteristics of inflammation.
INFLAMMATION
Inflammation is part of the complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. 5 As such, it is a protective attempt by the organism to remove the injurious stimuli and to initiate the healing process. At cellular and molecular level, inflammation is mediated by increased immune cell filtration and liquid mediators such as cytokines. The cellular components are leukocytes, granulocytes, and epithelial cells. Leukocytes normally reside in blood and must move into the inflamed tissue through extravasation to aid in inflammation. Granulocytes release enzymatic granules and inflammatory mediators that develop and maintain the inflammatory response. Epithelial cells provide the first line innate immune defense to protect the body against invasion of pathogens and harmful irritants. Acute inflammation is generally mediated by granulocytes, whereas chronic inflammation is mediated by mononuclear cells, dendritic cells, and macrophages. The classical signs of acute inflammation are pain, heat, redness, swelling, and loss of function, but current research has shown that inflammatory responses can be critical to good heath, even when the typical signs of inflammation are not present.
Inflammation in Atherogenesis
A research study has demonstrated that atherogenesis begins with the recruitment of inflammatory cells to the intima (Fig. 2 ). 6 Activated vascular endothelial cells express leukocyte adhesion molecules that capture and recruit blood monocytes. The monocytes then express scavenger receptors and take up modified lowdensity lipoprotein (LDL) particles such as oxidized LDL (oxLDL), leading to the formation of foam cells and the mature lipid-laden macrophages of the plaque's core. These cells can produce pro-inflammatory mediators, reactive oxygen species, and tissue factor pro-coagulants that amplify local inflammation and promote thrombotic complications.
T cells also enter the intima and send decisive regulatory signals. For example, T helper 1 (Th1) cells secrete the signature cytokine interferon (IFN)-g, which can activate vascular wall cells and macrophages and magnify and sustain the inflammatory response in the intima. Regulatory T (Treg) cells produce interleukin (IL)-10 and transforming growth factor (TGF)-b, 2 cytokines considered to exert anti-inflammatory actions. At the same time, B cells accumulate and organize in the perivascular tissue surrounding atherosclerotic arteries, where they produce circulating antibodies that may limit inflammation and mute atherogenesis.
In addition, triglyceride-rich lipoproteins such as very LDL, particularly those particles that bear apolipoprotein C-III (Apo-CIII) or apolipoprotein B (Apo-B), can instigate vascular inflammation through Toll-like receptor (TLR)-2 signaling.
Macrophage foam cells can efflux cholesterol through ATPbinding cassette transporters, which work in tandem.
Inflammation in Rheumatoid Arthritis
Rheumatoid arthritis is an autoimmune disease in which the body mistakenly attacks the lining, or synovium, of joints. 7 The symptoms include painful, warm, swollen joints, morning stiffness, fatigue, and nodules under the skin.
Symptoms appear when monocytes are attracted to the RA joint ( Fig. 3 ). Differentiating into activated macrophages, they secrete tumor necrosis factor (TNF) and IL-1. Tumor necrosis factor increases the expression of adhesion molecules on endothelial cells, which recruit more cells to the joint.
Chemokines, such as monocyte chemotactic protein (MCP)-1 and IL-8, are also secreted by macrophages and attract more cells into the joint. Interleukin-1 and TNF induce synovial fibroblasts to express cytokines (such as IL-6), chemokines (such as IL-8), and growth factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and matrix metalloproteinases (MMPs), which contribute to cartilage and bone destruction. Tumor necrosis factor contributes to osteoclast activation and differentiation. In addition, IL-1 mediates cartilage degradation directly by inducing the expression of MMPs by chondrocytes.
Inflammation in Dry Eye Disease
The inflammatory components of DED include both cells and mediators. The cells are mainly antigen-presenting cells (APCs), such as lymphocytes, dendritic cells, langerhans cells, macrophages, and T-cells (Th1, Th17, and Treg). They also include the epithelial cells of the cornea and conjunctiva. Human leukocyte antigens HLA-DR-positive cells have been proposed as a biomarker of DED in clinical trials. 8 The inflammatory mediators associated with DED pathogenesis can be categorized as ubiquitous inflammatory cytokines, 9, 10 Th1-related cytokines, [11] [12] [13] Th17-related cytokines, [13] [14] [15] [16] chemokines and their receptors, 13,17-21 metalloproteinase, 20, 22 and secretory phospholipases. [23] [24] [25] Like HLA-DR-positive cells, changes in tear cytokine expression in both humans 9, 12, 14, 15, 24 and animals [26] [27] [28] [29] [30] can be used as minimally invasive objective biomarkers to classify disease severity, elucidate disease mechanisms, and assess treatments. 31 
EVIDENCE OF INFLAMMATION AS CORE MECHANISM IN PATHOPHYSIOLOGY OF DRY EYE DISEASE
The 354 original studies revealed by the authors' search of relevant literature since January 1900, provide substantial evidence that the core mechanism in the pathophysiology of DED is inflammation. Specific studies are discussed below by the tissue or subjects under study. 
Cell or Tissue Culture Models
Of the studies found by the authors, 39 concern DED and inflammation as evaluated by cell or tissue culture models.
In study, a short-term desiccation (0-30 min) of human corneal epithelial cell line induced an increase in the expression of IL-6 and TNF-a, as well as an increase cell death. Cell death was partially suppressed by the addition of anti-IL-6 antibody. A long-term desiccation (.8 hr) of the same cells induced an increase in both IL-6 and IL-8. 32 However, human corneal epithelial cells treated with hyperosmolar shock alone (400-500 mOsm/kg for 12-48 hr) showed no effect on the constitutive expression of human beta-defensin-1 and -3 (hBD-1 and -3) nor on induction of hBD-2. However, in the presence of IL-1b, induction of hBD-2 and IL-6 expression was reduced as compared with IL-1b alone, suggesting that hyperosmolar shock may affect ocular surface inflammation through altering functions of key inflammatory cytokines. 33 The authors have shown that sPLA2-IIa together with TNF-a or IL-1b has a synergistic effect on the inflammatory cytokine/chemokine expression of the human conjunctiva. 34 
Animal Models
Dogs have been used in the DED research. Normal dogs have a limited level of apoptosis in nictitans lacrimal gland and conjunctival epithelial cells, whereas dogs with DED display an increased apoptosis in the same areas. Furthermore, such increase in apoptosis can be suppressed by a topical application of anti-inflammatory cyclosporine A, providing evidence of the mechanism of inflammation in DED. [35] [36] [37] The most frequently used animal models in DED studies involve mice. Based on the authors' literature research, the most active teams using mouse models are Pflugfelder, Stern Tables 4 and 5 .
Using a similar scopolamine-air ventilation desiccationinduction mouse model but with white BALB/C mice that have the same natural pla2g2a gene as in humans, the authors have conducted DED studies that confirmed the pivotal role of sPLA2-IIa (product of pla2g2a gene) in promoting inflammation on the ocular surface, especially when the ocular surface is under desiccation stress or in the presence of additional TNF-a and IL-1b. [23] [24] [25] 58 sPLA2-IIa not only supports ridding the tear film of bacterial pathogens, but also serves as the first ratelimiting enzyme for the inflammatory cascade to produce PGE2 and many other inflammatory mediators that drive the cycle of inflammation on the ocular surface. Furthermore, the authors demonstrated that after DE induction, the mouse that received eye drops containing solvent only developed a typical punctuated corneal keratopathy in corneal staining, whereas the mouse that received eye drops containing sPLA2 inhibitors displayed almost no staining, indicating that sPLA2 played a significant role in DE pathogenesis. The inhibition of sPLA2 may provide a pathway for therapeutics of DED and other inflammatory diseases of the ocular surface. 58 
Human Studies
A number of human studies have demonstrated increases in a variety of inflammatory cells in both non-Sjögren's and Sjögren's dry eye patients. Examples of such cells are the following:
• CD3 + and CD4 + T cells in conjunctival epithelium of Sjögren and non-Sjögren syndrome-associated DED. 59 • IL-7Ra-positive T cells. 60 • T cells (high CD4/CD8 ratio), 59 B cells, and macrophages. 61 • HLA-DR-positive APC in the conjunctiva. 59, 62 • IFN-g can also upregulate HLA-DR and intercellular adhesion molecule (ICAM)-1 in human conjunctival cells, which indicates that ocular surface cells can respond to and modulate inflammation. 63 Many human studies also point to the important inflammatory role played by cytokines, chemokines, and their receptors; for example:
• IL-2, IL-4, IL-5, IL-6, IL-8, IFN-g, TNF-a, and IL-1b. 64 • Inflammatory chemokines, macrophage inflammatory protein (MIP)-2, and chemokine receptors (CCR5). 18, 59, 65 • IL-1b, TNF-a, and MMP-9 and activates mitogen-activated protein kinase (MAPK) signaling pathways. 65, 66 • IL-6 protein and IL-1b, TNF-a, and IL-8 messenger RNA. 67 • IL-7. 60 That inflammation plays a key role in DED pathogenesis is also supported by the authors' own studies. We have shown that the HLA-DR-positive cell population is correlated with severity of DED 68 ; also concentrations of inflammatory cytokine/chemokines, especially IL-1b, IL6, IL8, IL-10, TNF-a, and IFN-g, are increased in the tears of patients with DED as compared with controls. 31, 64 
RESPONSES TO ANTI-INFLAMMATORY TREATMENTS CONSISTENT WITH THE PIVOTAL ROLE OF INFLAMMATION IN DED PROGRESSION
Several reports reveal improvement of DED symptoms and/or signs in patients treated with topical or systematic antiinflammatory drugs such as cyclosporin, and steroids:
• CsA proven to improve symptoms and objective tests (Johnson LN, 2007; http://clinicaltrials.gov/show/NCT01072526). 69, 70 • Corticosteroids effective anti-inflammatory therapy in DED (Have to be used carefully and preferentially in the short-term because of steroid side effects). 71 • Omega-3 essential fatty acids in dietary supplementation were found to be beneficial, although other reports were contradictory. [72] [73] [74] [75] FIG. 2. Atherogenesis and inflammation, adapted with permission from Libby et al. 6 Atherogenesis begins with the recruitment of inflammatory cells to the intima. Activated endothelial cells express leukocyte adhesion molecules that capture and recruit blood monocytes to the intima. These activated monocytes express scavenger receptors that permit the uptake of modified LDL particles, such as oxLDL). Cholesterol loading leads to the formation of foam cells, and ultimately leads to the mature lipid-laden macrophages of the plaque's core. These cells can produce pro-inflammatory mediators, reactive oxygen species, and tissue factor pro-coagulants that amplify local inflammation and promote thrombotic complications. Although fewer in number than the mononuclear phagocytes, T cells also enter the intima and send decisive regulatory signals. After antigen-specific activation, Th1 cells secrete the signature cytokine IFN-g, which can activate vascular wall cells and macrophages, and magnify and sustain the inflammatory response in the intima. 69, 70 • Anti-inflammatory therapy and/or immunomodulatory and antiapoptotic strategies may play an important role in the management of DED. 76, 77 • Acupuncture and homeopathy, as alternative therapies, associated with topical cyclosporine, are currently being tested. 78 Recently, the authors conducted a small randomized doubleblind clinical trial in DED subjects of systemic Omega 3 supplements. Comparison of cytokine levels in tears of patients who received placebo with those who received Omega-3 supplementa-tion for 3 months demonstrated an average fourfold decrease in IL-1b, TNF-a, and INF-g but fourfold increase in IL-6. 31 These results suggest that Omega-3 may decrease inflammatory cytokines or delay progression of DED inflammation. However, larger study populations and longer treatment would be needed to determine efficacy of Omega-3 in reducing tear cytokine concentrations and more clearly evaluate possible effects on signs and symptoms of DED.
OXIDATIVE STRESS AND THE PATHOGENESIS OF DRY EYE DISEASE
Oxidative stress is caused by an imbalance between the production of reactive oxygen species and the ability of a biological system's defense mechanisms to eliminate the stress. Such stress has been implicated in a variety of acute and chronic diseases, including atherosclerosis, myocardial infarction, fragile X syndrome, Parkinson disease, and Alzheimer disease. 79 In Japan, Tsubota et al have investigated a possible pathogenic role of oxidative stress in DED with a conditional knockout mouse line of mev-1 gene (Tet-Mev-1 mouse). The mev-1 gene encodes Cyt-1, the cytochrome b (560) large subunit of succinate-ubiquinone oxidoreductase in complex II of mitochondria (homologous to succinate dehydrogenase C subunit in humans). 80 As such, disruption of the mev-1 gene function causes excessive accumulation of superoxide anion and the oxidative stress in Caenorhabditis elegans. 81 Topical application of CCR2 antagonist is associated with significant improvement in DED and is reflected by a decrease in inflammation at the clinical, molecular, and cellular levels DED, dry eye disease; EGCG, epigallocatechin gallate; TLRs, Toll-like receptors. NKT cells are major sources of IL-13 in the conjunctival mucosa that regulates GC homeostasis 2010 Induction of Th17 Differentiation by Corneal Epithelial-Derived Cytokines 45 Th17 differentiation can be promoted by cytokines produced by the corneal epithelium that are exposed to hyperosmotic, microbial, and inflammatory stimuli 2010 Autoimmunity at the Ocular Surface: Pathogenesis and Regulation 46 Environmental, microbial, and endogenous stress, antigen localization, and genetic factors provide the triggers underlying the immunological events that shape the outcome of the diverse spectrum of autoimmune-based In one study, Tsubota et al showed that a functional knockout of mev-1 gene in mice caused a decrease in tear production with morphological changes, including leukocytic infiltration and fibrosis, and induced lacrimal dysfunction and DED. They concluded that inflammation induced by oxidative stress may initiate a functional decline in tear production. 80 In another study, the same team showed that Se-lactoferrin eye drops in high doses weakly improved dry eye, probably by suppressing the upregulation of heme oxygenase-1, cyclooxygenase-2, matrix metallopeptidase-9, and IL-6 while suppressing 8-Oxo-29deoxyguanosine (8-OHdG) production in the cornea. 82 Previous studies have shown that lactoferrin, a dominant glycoprotein of tears, has anti-inflammatory effects and promotes cell growth. Oral lactoferrin administration preserves lacrimal gland function in aged mice by attenuating oxidative damage and suppressing subsequent gland inflammation. Lactoferrin administration may thus reduce inflammatory cell infiltration and the MCP-1 and TNF-a expression levels in age-induced dry eye disease. 83 Taken together, the above studies suggest that oxidative stress may play a significant role in the pathogenesis of DED, probably through influencing ocular surface inflammation.
ADAPTIVE OR INNATE IMMUNITY, CHICKEN OR EGG: CANNOT TELL WHICH CAME FIRST, BUT THEY ARE INTEGRALLY CONNECTED
DED inflammation comprises both innate and adaptive immunity. 2, 38, 85 The initial acute response is an innate immune episode of DED likely trigged by environmental and/or microbial stresses. These stresses change the dynamics of tear film and the associated lacrimal gland, neural network, and ocular surface and initiate ocular surface nonspecific immune responses by activating immature APCs (such as dendritic cells, monocytes, NK cells, gdT cells, langerhans cells, macrophages, and ocular epithelial cells) through MAPK pathways and/or pattern recognition receptors. 85 The activated APCs then produce and release a variety of inflammatory mediators, such as cytokines, chemokines, MMPs, ICAMs, and phospholipases that further magnify the innate inflammatory responses.
Subsequently, mature APCs migrate into regional lymph nodes, where they initiate the adaptive immune episode by generating and maintaining dry eye-specific and ocular-specific autoreactive CD4 + T cells and autoantibody secreting B cells. Th17 cells then migrate through efferent blood vessels back to the ocular surface after breaking up the epithelial barriers and producing more mediators to promote lymphangiogenesis. They also facilitate pathogenic immunocytic infiltration that leads to further damage of the ocular surface and progression of a chronic cycle of inflammation.
Thus, the authors' working hypothesis is that the key mechanism in DED-related inflammation is not innate or adaptive immunity per se, but a chronic inflammatory cycle sustained by dysregulation of immunity ( Fig. 4 ).
PERSPECTIVES AND NOVEL STRATEGIES TO EFFECTIVELY TREAT DED INFLAMMATION
Based on this new hypothesis of DED pathogenesis, a cure or delay in DED progression may be achieved by any means that breaks the chronic cycle of ocular surface inflammation. Given the complex network of regulation and feedback, combined multiple targets are more plausible than single ones. Because sPLA2-IIa is the first enzyme in the cascade that produces inflammatory mediator PGE2 and a leading factor in the amplification of ocular surface inflammation under desiccation or compromised stress, 86 strategies to inhibit the function of sPLA2-IIa and block the production of inflammatory cytokines may be one way to block the cascade of inflammation, and thus interfere with the cycle of ocular surface inflammation.
The extensive and growing peer-reviewed published literature on DED from studies in tissue culture, animal models, and humans strongly supports the role of inflammation as part of the core pathogenesis of DED. The chronicity of the disease suggests that dysregulation of immune mechanisms leads to a cycle of continued inflammation. Changes in both innate and adaptive responses are likely "at play," and that understanding the dysregulation of the immune responses will lead to improved mechanisms for controlling inflammation of the ocular surface associated with DED. FIG. 4 . The current hypothesis of relationship between DED and inflammation. Dry eye disease inflammation comprises both innate and adaptive immunity. It starts with an acute innate immune in response to environmental and/or microbial stresses, leading to activation and maturation of APCs. The matured APCs migrate into regional lymph nodes to generate and maintain dry eye-specific and ocular-specific autoreactive CD4 + T cells, autoantibody secreting B cells, leading to the adaptive immunity. Th17 cells back to the ocular surface through efferent blood vessels to promote the production of inflammatory mediators, lymphangiogenesis, and pathogenic immunocytic infiltration, leading to further damage of the ocular surface and progression of a chronic cycle of inflammation. Thus, the key mechanism in DED-related inflammation is not innate or adaptive immunity per se, but a abnormal inflammatory cycle sustained by dysregulation of immune response. ACPs, antigen-presenting cells; DED, dry eye disease.
